Secondary Hyperparathyroidism Treatment Market 2019-2026: Sales Revenue, Growing CAGR Values, Industry Segments Analysis and Global Trends, Top Leaders, Strategy Profiling, Regional Statistics
SEATTLE, March 25, 2021, (PHARMIWEB) — Secondary hyperparathyroidism (SHPT) is a medical condition in which parathyroid hormone (PTH) is produced in excess by parathyroid glands in response to hypocalcemia the condition where blood calcium level is low. This condition mainly occurs in patients with kidney failure. Failing kidneys are unable to convert Vitamin A to its active form as they do not adequately excrete phosphate resulting in the formation of insoluble calcium phosphate by the body thus, leading to secondary hyperparathyroidism. Bone and joint pain, as well as limb deformities, are some of the major symptoms of secondary hyperparathyroidism (SHPT).
Get an exclusive sample copy of business report: https://www.coherentmarketinsights.com/insight/request-sample/1570
Treatment for SHPT involves surgical operation or consumption of prescribed drugs that help to maintain the level of parathyroid hormone, calcium, and phosphorus within the accepted targeted areas. According to the U.S. Food & Drug Administration (FDA) 2012, Secondary hyperparathyroidism is a serious chronic condition that affects a high percentage of patients receiving kidney dialysis. In the case of prognosis, if the SHPT is left untreated, the disease can lead to tertiary hyperparathyroidism and is then associated with hypercalcemia. According to the National Institute of Diabetes & Digestive & Kidney Diseases, the two prime reasons resulting in chronic kidney disease are diabetes and high blood pressure. Patients suffering from CKD, due to one of the reasons, if remain undetected can progress to irreversible kidney failure.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://bit.ly/39h8H3A
The growing incidence of chronic kidney diseases is one of the prime factors fueling the market growth of the global secondary hyperparathyroidism treatment market. According to the Centers for Disease Control & Prevention (CDC) 2017, 30 million people or 15% of the U.S. adults are estimated to have chronic kidney disease, out of which 48% suffer severely with reduced kidney function, however, they are not aware of having a CKD. Moreover, according to the National Kidney Foundation 2016, 10% of the population across the world are affected with chronic kidney diseases. In addition to this, growing research in the field of nephrology to develop new drugs and therapies for the treatment of secondary hyperparathyroidism is also expected to fuel market growth. For instance, Sanofi SA’s Hectorol capsules are undergoing Phase 3 clinical trials to evaluate the safety and efficacy of this medication in reducing the level of secondary hyperparathyroidism in pediatric patients with chronic kidney diseases at stage 3 and 4. The drug is expected to complete its study in December 2017, and be commercially available in the market. On the other side, side effects associated with secondary hyperparathyroidism treatment such as muscle spasm, diarrhea, and vomiting are projected to curb the growth of the market.
Based on region, the global secondary hyperparathyroidism treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global secondary hyperparathyroidism treatment market, and this can be attributed to increasing research and development of novel therapies and potential drugs for secondary hyperparathyroidism as well as a high prevalence of chronic kidney disease. According to the Centers for Disease Control & Prevention (CDC), in 2014, 118,000 people in the U.S. started treatment for ESRD, and 662,000 were living on chronic dialysis. Furthermore, Europe is expected to be the second-largest contributor in the secondary hyperparathyroidism treatment market, in terms of revenue and is projected to gain significant traction in the near future owing to launch of new drugs and therapies, to combat secondary hyperparathyroidism as well as the presence of significant population suffering from the disease in this region. For instance, in December 2016, Amgen’s drug etecalcetide (Parsabiv), received marketing approval in Europe by the European Commission for treatment of secondary hyperparathyroidism in adult patients with chronic kidney diseases. Furthermore, Asia Pacific is projected to be the fastest-growing region, and this can be attributed to the rising number of clinical trials by regional companies for the launch of new drugs. For instance, Kyowa Hakko Kirin China Pharmaceutical Co., Ltd is under Phase 4 clinical trial to determine the safety and efficacy of its new lead compound Cinacalet for treatment of patients suffering from mild to moderate SHPT and expected to be launched in the market by April 2019.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/secondary-hyperparathyroidism-treatment-market-1570
Key players operating in the global secondary hyperparathyroidism treatment market include AbbVie, Inc., Shire, Inc., OPKO Health, Amgen, Inc., Sanofi SA, F. Hoffmann-La Roche AG, Kyowa Hakko Kirin Co. Ltd., KAI Pharmaceuticals, Astellas Pharma, Inc., Deltanoid Pharmaceuticals, and Leo Pharma. Major players are focusing on innovation and new product development, to maintain their position in the market and enhance their share. For instance, in June 2016, OPKO Health introduced Rayaldee (calcifediol) for the treatment of SHPT in adults with stage 3 or 4 of chronic kidney disease.
The global secondary hyperparathyroidism treatment market by Coherent Market Insights is segmented on the basis of drug class and distribution channels.
On the basis of drug class
- Vitamin D Derivatives
- Phosphate Binders
- Calcium-Based Binders
- Non-Calcium Based Binders
Based on the distribution channel
- Hospital Pharmacies
- Retail Pharmacies
Table of Content
Global Secondary Hyperparathyroidism Treatment Market Research Report
Section 1: Global Secondary Hyperparathyroidism Treatment Industry Overview
Section 2: Global Economic Impact on Secondary Hyperparathyroidism Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Secondary Hyperparathyroidism Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Secondary Hyperparathyroidism Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire